Anzeige
Mehr »
Login
Montag, 07.04.2025 Börsentäglich über 12.000 News von 688 internationalen Medien
Nach sensationellem Forschungsdurchbruch! Welche Aktie am Montag outperformen könnte...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EEZB | ISIN: US72941H5090 | Ticker-Symbol: XMP0
NASDAQ
04.04.25
21:55 Uhr
0,781 US-Dollar
+0,006
+0,75 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PLUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PLUS THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0000,00014.03.

Aktuelle News zur PLUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrPlus Therapeutics files to sell 1.57B shares of common stock for holders2
31.03.PLUS THERAPEUTICS, INC. - 10-K, Annual Report2
PLUS THERAPEUTICS Aktie jetzt für 0€ handeln
28.03.H.C. Wainwright cuts Plus Therapeutics price target to $5.5010
28.03.Plus Therapeutics outlines REYOBIQ expansion plans and CNSide launch timeline5
27.03.Plus Therapeutics GAAP EPS of -$2.34 misses by $0.59, revenue of $5.82M beats by $0.29M6
27.03.PLUS THERAPEUTICS, INC. - 8-K, Current Report3
26.03.Plus Therapeutics Q4 2024 Earnings Preview4
26.03.A Peek at Plus Therapeutics' Future Earnings4
21.03.PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug9
21.03.Why Plus Therapeutics Inc. (PSTV) Surged On Thursday?10
20.03.Why Plus Therapeutics (PSTV) Shares Are Exploding Higher15
20.03.Why Plus Therapeutics Is Rising In Pre-market?305WASHINGTON (dpa-AFX) - Plus Therapeutics (PSTV) announced the FDA has conditionally accepted the company's new proprietary name, REYOBIQ, for its lead therapeutic candidate. The company noted...
► Artikel lesen
20.03.FDA akzeptiert bedingt neuen Namen für Plus Therapeutics Medikament13
20.03.FDA conditionally accepts new name for Plus Therapeutics drug5
20.03.Plus Therapeutics Inc.: Plus Therapeutics Introduces REYOBIQ, FDA-Accepted Proprietary Name for Lead Drug Candidate109REYOBIQ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus...
► Artikel lesen
17.03.Plus Therapeutics stock gains on Boral Capital Buy rating8
11.03.D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. in Connection with its up to $15.0 Million Private Placement336HOUSTON, TX / ACCESS Newswire / March 11, 2025 / On March 4th, Plus Therapeutics, Inc. (Nasdaq:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with...
► Artikel lesen
11.03.Plus Therapeutics Regains Nasdaq Compliance433WASHINGTON (dpa-AFX) - Plus Therapeutics (PSTV) announced that on March 7, 2025, Nasdaq confirmed the company's compliance with the minimum stockholders' equity requirement.As a result, PSTV...
► Artikel lesen
10.03.Plus Therapeutics regains compliance with Nasdaq minimum stockholders' equity requirement9
10.03.Plus Therapeutics Inc.: Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement164HOUSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company" or "Plus Therapeutics"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics...
► Artikel lesen
Seite:  Weiter >>
66 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1